康泰生物：公司产品管线已实现全生命周期布局，特别是瞄准极具增长潜力的成人免疫需求

Core Viewpoint - The company has established a comprehensive product pipeline targeting the growing adult immunization market, with a focus on various vaccines that have already been approved or are in development [1] Product Pipeline Summary - The company has already launched several vaccines, including: - Hepatitis B vaccine (20μg, 60μg) - 23-valent pneumococcal polysaccharide vaccine - Freeze-dried human rabies vaccine (human diploid cells) - Varicella live attenuated vaccine (for individuals aged 13 and above) [1] - The company is also developing additional adult vaccines, which include: - Quadrivalent influenza virus split vaccine - Adsorbed tetanus vaccine - 24-valent pneumococcal polysaccharide conjugate vaccine - Shingles vaccine - Respiratory syncytial virus (RSV) vaccine - Klebsiella pneumoniae vaccine - 60μg recombinant hepatitis B vaccine aimed at preventing recurrence in functionally cured hepatitis B patients [1]